Heart Failure Management in a Changing Paradigm

Published: 27 June 2022

  • Views:

    Views Icon 35122
  • Likes:

    Heart Icon 7


For this unique broadcast, Radcliffe Medical Education bring together a globally-renowned European and American faculty to participate in a roundtable discussion. Radcliffe’s roundtable discussions provide reflection on recently published data and examine what future developments can be expected at forthcoming events, through lively discussion and data presentations.


Prof Andrew Coats (University of Warwick, UK) leads proceedings, and is joined by Dr Shelley Zieroth (University of Manitoba, CA), Dr Javed Butler (University of Mississippi Medical Center, Jackson, MS) and Dr Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL) for an insightful presentation and a discussion.


This programme is supported by an educational grant from the Boehringer Ingelheim ​and Lilly Alliance

Learning Objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice

More from this programme

Part 1

Ejection Fraction in Context

This session considers the role of EF. Dr Zieroth will recap on historical use of EF and look at its limitations, prognostic information and therapeutic response. Finally, in her presentation, Dr Zieroth will run through trial design and exclusion of certain populations and elaborate what is the relevance of EF in today’s treatment paradigm.

Part 2

Life beyond Ejection Fraction

Dr Javed Butler will provide an overview of what the alternatives to EF are, focusing on functional measurements, quality of life and biomarkers.

Part 3

New data in HF and how to apply them to practice

Dr Prof Ponikowski will present new interesting data, emerging from recent studies and will provide insight of how the results can be applied to practice.

Part 4

Roundtable Discussion: HF management in a changing paradigm

Moderated by Prof Coats, this roundtable discussion, will give the faculty the opportunity to further discuss the HF landscape and examine what future developments can be expected.

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

Director of the Heart Failure and Heart Transplant Clinics

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.

She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of 

View full profile
Javed Butler

Javed Butler

Professor of Medicine

Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.

He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.


View full profile
Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.

Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.

He is an…

View full profile
Piotr Ponikowski

Piotr Ponikowski

Head of the Department of Heart Diseases

Piotr Ponikowski is Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. His research interests mainly include heart failure (HF), coronary artery disease and cardiac arrhythmias. He has been involved in numerous research projects, such as the benefits of physical rehabilitation in patients with chronic HF, assessment of metabolic derangements in HF (with special interest in iron deficiency), evaluation of reflex control in the cardiorespiratory system in order to optimise assessment and management of patients with HF. He has been involved in numerous clinical trials as main investigator, member of international steering committees, endpoint committees and advisory boards.

View full profile